Protease inhibitor and triple-drug therapy: Cellular immune parameters are not restored in pediatric AIDS patients after 6 months of treatment

AIDS

Volumn 12, Issue 18, 1998, Pages 2397-2406

  Chougnet, Claire ^a   Fowke, Keith R ^a   Mueller, Brigitta U ^a   Smith, Sharon ^a   Zuckerman, Judy ^a   Jankelevitch, Shirley ^a   Steinberg, Seth M ^a   Luban, Naomi ^b   Pizzo, Philip A ^a   Shearer, Gene M ^a  

^a NATIONAL CANCER INSTITUTE   (United States)

^b CHILDREN'S NATIONAL MEDICAL CENTER   (United States)

Author keywords

Antiretroviral therapy; Apoptosis; Cellular immunity; Cytokines; Interleukin 10; Interleukin 12; Pediatrics; Tumor necrosis factor receptors; Tumor necrosis factor

Indexed keywords

ANTIRETROVIRUS AGENT; CD4 ANTIGEN; CYTOKINE; MITOGENIC AGENT; PROTEINASE INHIBITOR; TUMOR NECROSIS FACTOR ALPHA; TUMOR NECROSIS FACTOR RECEPTOR;

ACQUIRED IMMUNE DEFICIENCY SYNDROME; ADOLESCENT; ADULT; APOPTOSIS; ARTICLE; CHILD; CLINICAL TRIAL; CYTOKINE PRODUCTION; HUMAN; HUMAN CELL; HUMAN IMMUNODEFICIENCY VIRUS INFECTION; INFANT; MAJOR CLINICAL STUDY; MONOCYTE; NONHUMAN; PHASE 1 CLINICAL TRIAL; PHASE 2 CLINICAL TRIAL; PRIORITY JOURNAL; T LYMPHOCYTE;

EID: 7844228420     PISSN: 02699370     EISSN: None     Source Type: Journal    
DOI: 10.1097/00002030-199818000-00008     Document Type: Article

References (35)

1. Clerici M, Stocks NI, Zajac RA, et al.: Detection of three distinct patterns of T helper cell dysfunction in asymptomatic, human immunodeficiency virus-seropositive patients. Independence of CD4+ cell numbers and clinical staging. J Clin Invest 1989, 84:1892-1899.
2. Lucey DR, Melcher GP, Hendrix CW, et al.: Human immunodeficiency virus infection in the US Air Force: seroconversions, clinical staging, and assessment of a T helper cell functional assay to predict change in CD4+ T cell counts. J Infect Dis 1991, 164:631-637.
3. Kelleher AD, Carr A, Zaunders J, Cooper DA: Alterations in the immune response of human immunodeficiency virus (HIV)-infected subjects treated with an HIV-specific protease inhibitor, ritonavir. J Infect Dis 1996, 173:321-329.
4. Autran B, Carcelain G, Li TS, et al.: Positive effects of combined antiretroviral therapy on CD4+ T cell homeostasis and function in advanced HIV disease. Science 1997, 277:112-116.
5. Connors M, Kovacs JA, Krevat S, et al.: HIV infection induces changes in CD4+ T-cell phenotype and depletions within the CD4+ T-cell repertoire that are not immediately restored by antiviral or immune-based therapies. Nature Med 1997, 3:533-540.
6. Pakker NC, Notermans DW, De Boer RJ, et al.: Biphasic kinetics of peripheral blood T cells after triple combination therapy in HIV-1 infection: a composite of redistribution and proliferation. Nature Med 1998, 4:208-214.
7. Mueller BU, Nelson RP, Sleasman J, et al.: A phase I/II study of the protease inhibitor Ritonavir in children with HIV infection. Pediatrics 1998, 101:335-343.
8. Mueller BU, Sleasman J, Nelson RP, et al.: A phase I/II study of the protease inhibitor Indinavir in children with HIV infection. Pediatrics 1998, 102:101-109.
9. Chehimi J, Starr SE, Frank I, et al.: Impaired interleukin 12 production in human immunodeficiency virus-infected patients. J Exp Med 1994, 179:1361-1366.
10. Chougnet C, Wynn TA, Clerici M, et al.: Molecular analysis of decreased IL-12 production in individuals infected with the Human Immunodeficiency Virus. J Infec Dis 1996, 174:46-53.
11. Gougeon ML, Lecoeur H, Dulioust A, et al.: Programmed cell death in peripheral lymphocytes from HIV-infected persons. Increased susceptibility to apoptosis of CD4 and CD8 T cells correlates with lymphocyte activation and with disease progression. J Immunol 1996, 156:3509-3520.
12. Clerici M, Sarin A, Coffman RL, et al.: Type 1/type 2 cytokine modulation of T-cell programmed cell death as a model for human immunodeficiency virus pathogenesis. Proc Natl Acad Sci USA 1994, 91:11811-11815.
13. Baumler CB, Bohler T, Herr I, Benner A, Krammer PH, Debatin KM: Activation of the CD95 (APO-1/Fas) system in T cells from HIV1-infected children. Blood 1996, 88:1741-1746.
14. Godfried MH, van der Poll T, Mulder JW, et al.: Soluble tumor necrosis factor receptors as surrogate markers for the assessment of zidovudine treatment in asymptomatic HIV-1 infection. J Acquir Immune Defic Syndr Hum Retrovirol 1995, 10:531-539.
15. Bilello JA, Stellrecht K, Drusano GL, Stein DS: Soluble tumor necrosis factor-alpha receptor type II (sTNF alpha RII) correlates with human immunodeficiency virus (HIV) RNA copy number in HIV-infected patients. J Infect Dis 1996, 173:464-467.
16. Rizzardi GP, Barcellini W, Tambussi G, et al.: Plasma levels of soluble CD30, tumour necrosis factor (TNF)-alpha and TNF receptors during primary HIV-1 infection: correlation with HIV-1 RNA and the clinical outcome. AIDS 1996, 10:F45-F50.
17. Hestdal K, Aukrust P, Muller F, et al.: Dysregulation of membrane-bound tumor necrosis factor-alpha and tumor necrosis factor receptors on mononuclear cells in human immunodeficiency virus type 1 infection: low percentage of p75-tumor necrosis factor receptor positive cells in patients with advanced disease and high viral load. Blood 1997, 90:2670-2679.
18. Trauger RJ, Ferre F, Daigle AE. et al.: Effect of immunization with inactivated gp120-depleted human immunodeficiency virus type 1 (HIV-1) immunogen on HIV-1 immunity, viral DNA, and percentage of CD4 cells. J Infect Dis 1994, 169:1256-1264.
19. Ahmed AR, Blose DA: Delayed-type hypersensitivity skin testing. A review. Arch Dermatol 1983, 119:934-945.
20. Raszka WV, Moriarty RA, Ottolini MG, et al.: Delayed-type hypersensitivity skin testing in human immunodeficiency virus-infected pediatric patients. J Pediatr 1996, 129:245-250.
21. Schweder T, Spjotvoll E: Plots of p-values to evaluate many tests simultaneously. Biometrika 1982, 69:493-502.
22. Hochberg W: A sharper Bonferroni procedure for multiple tests of significance. Biometrika 1988, 75:802-802.
23. Aukrust P, Liabakk N-B, Muller F, Lien E, Espevik T, Froland SS: Serum levels of TNF-α and soluble TNF receptors in human immunodeficiency virus type 1 infection - correlations to clinical, immunologic, and virological parameters. J Infect Dis 1994, 169:420-424.
24. Weiss M, Martignoni M, Petropoulou T, Solder B, Belohradsky BH: Increased serum levels of soluble tumor necrosis factor receptors (sTNF-Rs) in children and adolescents with vertically and horizontally transmitted HIV infection. Infection 1996, 24:301-308.
25. Codfried MH, van der Poll T, Weverling GJ, et al.: Soluble Receptors for Tumor Necrosis Factor as predictors of progression to AIDS in asymptomatic Human Immunodeficiency Virus Type 1 infection. J Infect Dis 1994, 169:739-745.
26. Corriel MD, Kniker WT, McBryde JL, Lesourd BM: Cell-mediated immunity in schoolchildren assessed by multitest skin testing. AJDC ??1985, 139:141-146.
27. Deeks SG, Smith M, Holodniy M, Kahn JO: HIV-1 Protease inhibitors. A review for clinicians. JAMA 1997, 277:145-153.
28. Yoo J, Chen H, Kraus T, et al.: Altered cytokine production and accessory cell function after HIV-1 infection. J Immunol 1996, 157:1313-1320.
29. Taoufik Y, Lantz O, Wallon C, Charles A, Dussaix E, Delfraissy JF: Human immunodeficiency virus gp120 inhibits interleukin-12 secretion by human monocytes: an indirect interleukin-10-mediated effect, Blood 1997, 89:2842-2848.
30. Berger S, Chandra R, Balló H, Hildenbrand R, Stutte HJ: Immune complexes are potent inhibitors of interleukin-12 secretion by human monocytes. Eur J Immunol 1997, 27:2994-3000.
31. Harrison TS, Levitz SM: Priming with IFN-γ restores deficient IL-12 production by peripheral blood mononuclear cells from HIV-seropositive donors. J Immunol 1997, 158:459-463.
32. Chougnet C, Thomas E, Landay AL, et al.: CD40 Ligand and IFN-γ synergistically restore IL-12 production in HIV-infected patients, Eur J Immunol 1998, 28:646-656.
33. Gorochov G, Neumann AU, Kereveur A, et al.: Perturbation of CD4+ and CD8+ T-cell repertoires during progression to AIDS and regulation of the CD4+ repertoire during antiviral therapy. Nature Med 1998, 4:215-221.
34. Mackall CL, Fleisher TA, Brown MR, et al.: Age, thymopoiesis, and CD4+ T-lymphocyte regeneration after intensive chemotherapy. N Engl J Med 1995, 332:143-149.
35. Mordmuller BG, Melzger WG, Juillard P, et al.: Tumor necrosis factor in Plasmodium falciparum malaria: high plasma level is associated with fever, but high production capacity is associated with rapid fever clearance, Eur Cytokine Netw 1997, 8:29-35.